Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$1.11 USD
+0.03 (2.78%)
Updated May 24, 2024 03:59 PM ET
After-Market: $1.09 -0.02 (-1.80%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
APTO 1.11 +0.03(2.78%)
Will APTO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for APTO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APTO
What Makes Aptose Biosciences (APTO) a New Buy Stock
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
APTO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
Horizon (HZNP) Completes Enrollment in Phase IV TED Study
Other News for APTO
Buy Rating for Aptose Biosciences on Tuspetinib’s Promising AML Study and Synergistic Potential
Aptose Biosciences price target lowered to $6 from $15 at Canaccor15
Aptose Biosciences: Q1 Earnings Snapshot
Aptose Reports Results for the First Quarter 2024
Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript